Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,670 JPY | +1.91% | +0.95% | +15.53% |
05-28 | Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview?? Monitoring System | CI |
05-15 | Correction: Terumo’s Profit Up 47% in Fiscal 2024 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With an expected P/E ratio at 36.82 and 31.31 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.4 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.53% | 25.22B | A- | ||
-7.16% | 178B | C+ | ||
-1.23% | 107B | C | ||
-4.86% | 67.04B | A | ||
-4.28% | 47.23B | B- | ||
+10.32% | 44.62B | B- | ||
+8.14% | 42.5B | B+ | ||
-5.88% | 24.14B | A- | ||
-5.38% | 23.69B | B | ||
+1.38% | 22.04B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4543 Stock
- Ratings Terumo Corporation